Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Rejuvenate Biomed

Request full access

Science based healthy aging company developing prescription drugs in healthy aging by repositioning approved drugs

Diepenbeek, BelgiumFounded 2017Biotech & Life Sciences

About Rejuvenate Biomed

Rejuvenate Biomed is a Belgian clinical-stage biotechnology company focused on tackling the root causes of aging. The firm was founded in October 2017 by Ann Beliën, PhD, who now serves as the CEO. Dr. Beliën established the company after a nearly two-decade career at Janssen, a Johnson & Johnson pharmaceutical company, where she gained extensive experience in drug development, from laboratory research to market launch, across areas like oncology, neurology, and immunology. Her background includes a PhD from the University of Irchel in Zurich, a master's degree from the Free University of Brussels (VUB), and a postdoctoral fellowship at ETH Zurich, culminating in strategic roles at Johnson & Johnson, including as a member of the Janssen Prevention Center's management board.

The company's core business revolves around its proprietary drug discovery platforms, CombinAge™ and CelegAge™. The AI-enabled in silico platform, CombinAge™, uses network biology and large datasets to identify and repurpose existing, safe molecules into novel combination drugs targeting longevity pathways. This is complemented by the in vivo CelegAge™ platform, which validates these findings. This dual-platform strategy enables Rejuvenate Biomed to create a pipeline of therapeutics aimed at preventing or delaying the onset of multiple age-related diseases, including neuromuscular, musculoskeletal, metabolic, and neurodegenerative conditions. In August 2024, the company announced a partnership with data and AI firm SAS to enhance its discovery capabilities using the SAS Viya cloud platform, making advanced analytics more accessible to researchers.

Rejuvenate Biomed's business model is centered on developing these proprietary drug candidates through clinical trials and eventually bringing them to market, targeting the significant unmet medical need for age-related ailments. The company has successfully secured funding to advance its pipeline, raising a total of $22M over two rounds. This includes a €3.2 million Series A in March 2021 and a €15.7 million ($18.2M) Series B round in October 2021, with key investors like Vesalius Biocapital III and Rejuveron Life Sciences. The company is headquartered at the Health Campus in Diepenbeek, Belgium, and is a resident of Johnson & Johnson Innovation, JLABS, a life sciences incubator.

The lead drug candidate, RJx-01, is an orally administered combination of galantamine and metformin, designed to treat sarcopenia—the age-related loss of muscle mass and function. In October 2023, Rejuvenate Biomed announced that RJx-01 had successfully completed a Phase 1b clinical trial involving healthy elderly subjects. The trial met all its primary and secondary endpoints, demonstrating a good safety profile and excellent bioavailability. The study showed that RJx-01 led to meaningful improvements in muscle strength recovery, function, and fatigue resistance. Following these positive results, the company is preparing for a Phase 2b program, which began in 2024. A Phase 2 trial for RJx-01 in treating muscle weakness associated with Chronic Obstructive Pulmonary Disease (COPD) was initiated in May 2025.

Source: Dealroom company data

At a glance

Status
Operational
Employees
15
Open positions
None listed
Dealroom signal
70.5/100
Industry
Health
Sub-industry
Pharmaceutical
Sector
Biotechnology, Biotech and Pharma, Hard Tech, Woman Founder, Longevity, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Oct 2021 $17M $69M Vesalius Biocapital Partners · Centenara Labs ↗
SERIES A✓Equity / VC Mar 2021 $3.5M $14M Vesalius Biocapital Partners ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearEBITDAMarginProfitMargin
2026 — —
2025 — —
2024 — —
2023 — —
2022 — —
2021 — —
2020 — —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Rejuvenate Biomed website traffic

Latest recorded traffic for Rejuvenate Biomed is 1.2K monthly website visits, up 20% over the last three months. Rejuvenate Biomed's team grew 0% over the past year.

Latest monthly visits1.2K 3-month web change+20% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Rejuvenate Biomed in the Diepenbeek ecosystem

Live from Dealroom

The Rejuvenate Biomed office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • VLAIO- Team Bedrijfstrajecten Crossroads France-Wallonie-Vlaanderen

Series A2 investors entered at this stage

  • Vesalius Biocapital Partners
  • Centenara Labs

Other known investors1 additional known investor

  • Samuel Caulier
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇧🇪 Belgium100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Rejuvenate Biomed on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Rejuvenate Biomed’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.